Advertisement

Controversially discussed indications for immunization

  • Sieghart Dittmann
Part of the Birkhäuser Advances in Infectious Diseases book series (BAID)

Abstract

The indication for immunization in general or indications for selected vaccines are sometimes controversially discussed by parents, the media and even by some parts of the medical community. This controversial discussion can cause confusion for people who want to make decisions about immunization for their children or themselves. There is clearly a need for accurate and evidence-based information about indications and effectiveness of vaccines, as well as about the risks from natural diseases compared with potential risks of adverse events following immunization. This chapter deals with (i) immunization as a safe and very effective disease prevention measure, (ii) indications for immunization of selected risk groups, and (iii) contraindications and false contraindications. The first part raises the most controversial questions (many diseases already disappeared due to improved socioeconomic conditions before vaccines were introduced; when a disease is gone there is no need to continue with immunization; natural immunity is better than vaccine-induced immunity; many vaccines are useless and not able to prevent disease; multiple immunizations overload the immune system; some vaccines are not safe and cause more complications than the natural disease) and tries to provide evidence-based answers. The second part deals with controversially discussed indications/contraindications for selected risk groups such as pregnant and breast-feeding women, pre-term babies, individuals with chronic diseases or immunodeficiency, patients with bleeding disorders and patients receiving anticoagulant medication. In the last part, genuine contraindications against distinct vaccines are discussed as well as health conditions falsely believed by the physician or the health worker to constitute a contraindication.

Keywords

Sudden Infant Death Syndrome Case Fatality Rate Pertussis Vaccine Measle Vaccine Oral Poliovirus Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dittmann S (2006) Elimination der Poliomyelitis. Polio-Nachrichten 2: 11–12Google Scholar
  2. 2.
    Dittmann S (2001) Vaccine safety: risk communication — a global perspective. Vaccine 19: 2446–2456PubMedCrossRefGoogle Scholar
  3. 3.
    Campbell H, Ramsay M, Gungabissoon U, Miller E, Andrews N, Mistry A, Mallard R, Borrow R (2004) Impact of the meningococcal C conjugate vaccination programme in England. Summary Surveillance Report from the Health Protection Agency, Centre for Infections Immunisation Department to end December 2004.Google Scholar
  4. 4.
    Centers for Disease Control and Prevention (2002) Epidemiology and prevention of vaccine-preventable diseases. In: Atkinson W, Hamborsky J, McIntyre L, Wolfe S (eds): The Pink Book, 9th edn, Appendix G: Reported cases and deaths for vaccine-preventable diseases. Public Health Foundation, Washington, D.C.Google Scholar
  5. 5.
    Six common misconceptions about vaccination and how to respond to them. htpp://www.cdc/nip/publications/6mishome.htm (accessed August 14, 2006)Google Scholar
  6. 6.
    Offit PA, Quarles J, Gerber MA, Hackett CJ, Marcuse EK, Kollman TR, Gellin BG, Landry S (2002) Addressing parents’ concerns: do multiple vaccines overwhelm or weaken the infant’s immune system? Pediatrics 109:124–129PubMedCrossRefGoogle Scholar
  7. 7.
    Public Health Agency of Canada (2002) Talking with patients about immunization. In: Canadian Immunization Guide 2002, Public Health Agency of Canada, Ottawa, 42–54.Google Scholar
  8. 8.
    Responding to questions and concerns about immunization. In: Australian Immunization Handbook, 8th edn 2003, online. htpp://www9.health.gov.au/immhandbook (accessed August 14, 2006)Google Scholar
  9. 9.
    Global Advisory Committee on Vaccine Safety (2003) MMR and autism. Weekly Epidemiol Rec 78: 18Google Scholar
  10. 10.
    Global Advisory Committee on Vaccine Safety (2005) Thiomersal: neurobehavioural studies in animal models. Wkly Epidemiol Rec 80: 3–4Google Scholar
  11. 11.
    Institute of Medicine Immunization Safety Reviews: Measles-mumps-rubella vaccine and autism. National Academy Press, Washington DC 2001. http://www.cdc.gov/nip/news/iom-04-24.htm (accessed August 14, 2006)Google Scholar
  12. 12.
    US Centers for Disease Control. Vaccines and autism — references. http://www.cdc.gov/nip/vacsafe/concerns/autism/autism-ref.htm (accessed August 14, 2006)Google Scholar
  13. 13.
    Davis RL, Kramarz P, Bohlke K, Benson P, Thompson RS, Mullooly J, Black S, Shinefield H, Lewis E, Ward J et al (2001) Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease. Arch Pediatr Adolesc Med 155: 354–359PubMedGoogle Scholar
  14. 14.
    US Centers for Disease Control. Measles vaccine and inflammatory bowel disease — references. http://www.cdc.gov/nip/vacsafe/concerns/autism/ibd. htm#references (accessed August 14, 2006)Google Scholar
  15. 15.
    (2002) Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders. National Academy Press, Washington, D.C.Google Scholar
  16. 16.
    (2003) Immunization Safety Review: Vaccinations and Sudden Unexpected Death in Infancy. National Academy Press, Washington, D.C.Google Scholar
  17. ]17
    (2002) Recommendations of the Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization. Morb Mortal Wkly Rep 51: No RR-2.Google Scholar
  18. 18.
    American Academy of Pediatrics (2003) Immunocompromised children. In: LK Pickering (ed): 2003 Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL, 69Google Scholar
  19. 19.
    Moss WJ, Clements CJ, Halsey NA (2003) Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 81: 61–70PubMedGoogle Scholar
  20. 20.
    EPI Vaccines in HIV-infected Individuals. htpp://www.who.int/vaccines-diseases/diseases/HIV.shtml (accessed August 14, 2006)Google Scholar
  21. 21.
    Contraindications for childhood vaccinations. htpp://www.cdc.gov/nip/recs/contraindications.htm (accessed August 14, 2006)Google Scholar
  22. 22.
    (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 49: RR-10Google Scholar
  23. 23.
    Avery RK, Ljungman P (2001) Prophylactic measures in the solid-organ recipient before transplantation. Clin Infect Dis 33(Suppl 1): 15–21CrossRefGoogle Scholar
  24. 24.
    Stark K, Günther M, Schönfeld C, Tullius SG, Bienzle U (2002) Immunisations in solid-organ transplant recipients. Lancet 359: 957–965PubMedCrossRefGoogle Scholar
  25. 25.
    Ljungman P (2004) Immunization in the immunocompromised host. In: SA Plotkin, WA Orenstein (eds): Vaccines, 4th edn. Saunders, Philadelphia, 155–168Google Scholar
  26. 26.
    (1998) Contraindications for vaccines used in EPI. Wkly Epidemiol Rec 63: 279–281Google Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2007

Authors and Affiliations

  • Sieghart Dittmann
    • 1
  1. 1.BerlinGermany

Personalised recommendations